New diabetes drugs and their impact on blood sugar control and worsening of diabetic eye disease

Intensive glycemic control may be associated with early worsening of diabetic retinopathy (EWDR) in patients treated with new-generation antidiabetic agents, particularly with glucagon-like peptide-1 receptor agonists (GLP1-RA).

• Rapid reductions in HbA1c levels may increase the risk of EWDR, despite long-term benefits in microvascular complications.
• Emerging evidence suggests a link between novel antidiabetic agents, including GLP1-RA, and EWDR, though findings are inconsistent across studies.
• Higher baseline HbA1c and significant initial HbA1c reductions are identified as risk factors for EWDR.
• Patients with a longer duration of diabetes and more advanced stages of diabetic retinopathy at baseline may also be at greater risk of EWDR.
• Mild or moderate non-proliferative diabetic retinopathy does not appear to be at higher risk for progression.

Simplified